Wilmer Cutler Pickering Hale and Dorr has advised PTC Therapeutics, Inc. Davis Polk advised the representative of several initial purchasers. PTC Therapeutics, Inc., a publicly-traded global...
PTC Therapeutics Raises $550 Million in Convertible Notes Offering
Terns Pharmaceuticals Completes $747.5 Million Public Offering of Common Stock
Wilmer Cutler Pickering Hale and Dorr has advised Terns Pharmaceuticals. Davis Polk has advised the representative of the underwriters. Terns Pharmaceuticals, Inc., a clinical-stage oncology company...
Terns Pharmaceuticals’ $172.7 Million IPO
Wilmer Cutler Pickering Hale and Dorr and Cooley advised on Terns Pharmaceuticals, Inc. on the offering, and Davis Polk & Wardwell advised the underwriters. Terns Pharmaceuticals,...
Voyager Therapeutics’ $100 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics, Inc. on the offering, and Cooley advised the underwriters. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced an underwritten public offering...
Voyager Therapeutics’ Capsid License Agreement and Strategic Collaboration with Novartis
Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...
Arvinas’ $350 Million Private Placement
Wilmer Cutler Pickering Hale and Dorr advised Arvinas, Inc. on the transaction. Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas”) announced that it entered into a securities purchase agreement with a...
Inozyme Pharma’s Common Stock Public Offering
Wilmer Cutler Pickering Hale and Dorr represented Inozyme Pharma and Shearman & Sterling represented the underwriters in the offering. Inozyme Pharma, Inc. announced the closing of its...
Voyager Therapeutics’ Collaboration Agreement with Neurocrine Biosciences
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics on the deal. Voyager Therapeutics announced that it entered into a strategic collaboration agreement with Neurocrine Biosciences...
Voyager Therapeutics’ License Option Agreement with Novartis
WilmerHale advised Voyager Therapeutics on the deal. Voyager Therapeutics, a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, announced it entered into...
Carisma’s Collaboration Agreement with Moderna
Wilmer Cutler Pickering Hale and Dorr advised Carisma Therapeutics Inc. on the deal. Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, announced a strategic collaboration...
Sanofi’s Acquisition of Tidal Therapeutics
Wilmer Cutler Pickering Hale and Dorr LLP advised Sanofi on the deal. Sanofi, a global biopharmaceutical company focused on human health, announced its acquisition of Tidal...